REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
|Articles|December 16, 2021
Daily OTC Pearl: Neosporin
Author(s)Saro Arakelians, PharmD
Neosporin prevents/treats only bacterial skin infections.
Advertisement
OTC/Lifestyle Pearl of the Day: Neosporin
Indication: Neosporin helps prevent infection of minor cuts, scrapes, and burns.
Insight:
- Neosporin is available without a prescription for self-medication.
- Do not use this product over large areas of the body.
- This product contains
neomycin ,bacitracin , andpolymyxin , which areantibiotics that work by stopping the growth of bacteria. - This medication prevents/treats only bacterial
skin infections. - It will not work for other types of
skin infections (e.g., infections caused by fungi, viruses). - Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.
- Application is usually 1 to 3 times a day to the affected area.
Sources:
Advertisement
Related to this article
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
2
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
3
Oncology Pharmacists Reduce Adverse Drug Reactions in Hematologic Cancer Care
4
Recap: Tirzepatide Is Approved to Cut Cardiovascular Risk in Type 2 Diabetes
5